Are there clinically significant differences between anti-COVID-19 vaccines? – Global issues

A health worker prepares to vaccinate her colleague Kovid 19 at a hospital in Mogadishu, Solia. In a video message to the World Health Organization on May 24 WHOUN Secretary-General Antonio Guterres “warns against threats”Two speed global response“It’s a matter of concern that he has repeatedly expressed.” Sadly, until we act now, we face a situation where rich countries vaccinate most people and open up their economies, while the virus travels to poor countries and suffers deeply. Credit: UNICEF / Ismail Texta
  • Thoughts Sunil J. Vimalavansa (byNew Jersey, USA)
  • Inter Press Service

There are no significant differences in efficacy between different types of individual vaccines: mRNA vaccines (e.g., Pfizer and Moderna), Adenovirus vector vaccines (E.g., AZN, J&J, and Sputnik V) and Inactivated SARS-CoV-2 virus vaccines (E.g., Synovac and Valneva) to prevent serious complications and death.

If there is no contraindication or basic reason or belief not to vaccinate, keeping in mind the urgency, individuals should take the vaccine given to them.

Efficacy of COVID vaccines:

According to global data, covidia-related complications account for about 1% of the adult population requiring hospitalization. By default, the reported efficacy of mRNA vaccines is ~%.

Therefore, the average efficacy of all COVID vaccines is approximately 0% (0. / 86 / 0.4 xx100). However, none of these vaccines completely prevent infection, transmission, sustainable damage or death.

The rate of complication can be significantly reduced Vitamin D supplementation before infection Or At the time of hospitalization (Mercola 2020; Wimalawansa, 2020) Concentration].

Most hospitalized COVID-19 patients have a 2 (OH) D level of less than 20 ng / mL, while the vast majority of deaths from COVID are less than 10 ng / mL. It is noteworthy that more than oc0 ng / mL of autocrine (within each cell) and paracrine (adjacent cells) are required for the proper operation of signaling and immune cell functions.

Fighting these antibodies is essential for fast and well-regulated immune responses. In the absence, people develop complications.

Types of SARS-CoV-2 vaccines:

The mRNA vaccine for other diseases has never been sent out for clinical trials for human disease. SARS-CoV-2 produces rapid immune responses because the insertions within the micro-lipid particles allow a large fraction of the viral spike protein to be produced in large quantities. The human immune system attacks and removes those foreign proteins.

Spike has a high affinity for protein ACE2 receptor protein Due to the sequence similarity of ACE2 located in human epithelial cell membranes in the lungs, gastrointestinal tract, blood vessels, etc. and ACE2-SARS.CoV-2 Complexly, antibodies produced against spike proteins can damage normal cells in the presence of a weakened immune system.

Why are there some developmental complications, others not?

Following natural infections and vaccinations, different types of antibodies produced by immune cells. Some of these can cross-react with ACE2 receptor proteins. Vitamin D is important for the proper functioning of the immune system. Vitamin D deficiency weakens the innate and adaptive responses and allows harmful hyper-inflammation (Cytokine – Hurricane) Responses.

Therefore, individuals with weakened immune systems have a higher risk of antigenic cross-reactivity, autoimmune response, and spontaneous antibody formation, which increases the risk of complications from SARS.Kov-2 (e.g. cytokine-storm and death).

Inactivated viral vaccines are less commonly used in Western countries, despite the benefits of producing a broader immune response against nucleocapsid proteins and spike proteins. In contrast, mRNA and adenoviral vector vaccines present only a fraction of the spike protein antigen to the immune system.

Thus, mRNA vaccines have a narrow specificity of antibodies, which can be a detriment in the long run.

The effectiveness of the vaccine group cannot be compared:

The condition and vaccine test time were quite different. MRNA or adenovirus vector vaccines performed no head-to-head comparable RCTs to compare against conventional inactivated viral vaccines, the safety of which is well understood.

Heavy promotions, especially by large investors and governments, are driven by the high profits of patent-based, novel plants of mRNA and viral vector vaccine companies. Despite the claims of companies, pundits and mass media, the effectiveness of mRNA and viral vector vaccines cannot be considered superior to traditional inactivated virus vaccines.

Vaccinated RCTs were performed under various conditions:

The mRNA for RCT and EUA was straightforward to obtain approval for vaccines. These RCTs were conducted in the United States during the summer and fall of the 20V0, before the emergence of the COVID-1 var variant. Some of these differences have evolved into a spike protein for the ACE2 receptor to facilitate their entry into our cells.

As the vaccination program expands, variants are evolving, avoiding double (e.g., Indian variants) and multi-mutants resistance. Mutations generate different spike-protein sequences (A) to remove recognition by antibodies and killer cells, and (B) to increase infectivity. The risk of such mutations is much lower than mRNA and viral vector vaccines.

Summer mRNA vaccine tests and include people with high average vitamin D concentrations with less severe symptoms. In contrast, viral vector vaccines and inactivated viral vaccines take longer to obtain EUA due to the much-needed complication.

These RCTs were mainly conducted outside the United States in the fall and winter, when multiple variants appeared and when COVID-1 spread again.

Effective versus vaccine side effects:

There are no questions about the benefits of the COVID-vaccine in adults. Given the varied nature and rapid deployment of RCTs, there is insufficient comparative data to conclude that one vaccine is more effective than another.

In addition, the analysis of incomplete reports and adverse reactions is a matter of concern, especially long-term adverse effects. For those with mild to moderate risks, such as children from Covid 1, these vulnerable risks should be considered more carefully in light of the limited personal benefits of the vaccine.

The ill effects of the vaccine are the subject of ongoing research and controversy, and therefore communication should be allowed freely. Instead, such discussions are abused by suppressing: Administrators remove posts from social media sites under the pretext of undermining public confidence in COVID-19 vaccines.

Individuals should be provided with facts: they have the right to know the advantages and disadvantages and to make their own decisions. In addition Vitamin D deficiencyEmerging data suggest that adverse effects are specific to a particular vaccine group, perhaps, with underlying risks and individual characteristics, such as sex and age.

Duration of uncertainty and efficacy of vaccines:

Despite baseless claims by vaccine makers and some high-ranking administrators, claims that the immunization period after vaccination is up to five years is a mere estimate.

Immunity to natural infections and COVID vaccines is uncertain. Anyway, by extrapolating from SARS experience, post-vaccine immunity 1 can last longer than 18 months, which hinders the development of global herd bone resistance.

Vitamin D adequacy coordinates the benefits of the vaccine:

The most beneficial aspect of the vaccine and Vitamin D adequacy Preventing hospitalization, complications of oxygen and ICU use, and death. Therefore, vaccination with vitamin D adequacy should also prevent post-covid syndrome, also called ‘long COVID’, which is a misnomer.

Post-covid-1nd syndrome mainly occurs in the central nervous system or other places where the SARS-CoV-2 virus can prevent incomplete immune responses, especially among them. With severe vitamin D deficiency And, therefore, having a less strong immune system.

Vitamin D adequacy prevents post-COVID syndrome. It remains to be seen whether the vaccine will prevent post-COVID-19 syndrome, but it remains to be seen.

* Sunil J. Vimalavansa, MD, PhD, MBA, DSC, Professor of Medicine, Endocrinology and Nutrition, Director Cardiometabolic Institute, USA[email protected]

Follow @IPNewsUNB Bureau
Follow IPS New UN Bureau on Instagram

© Inter Press Service (2021) – All rights reservedOriginal Source: Inter Press Service


Leave a Comment